GARDEN CITY, N.Y. -- (BUSINESS WIRE) -- ImaCor Inc., the fast-growing developer of the world’s only hemodynamic transesophageal echocardiography (hTEE™) management device, announced the second and third symposia in a planned series of academic events presenting hTEE clinical evidence. These additions to ImaCor’s 2013 educational program focus on hTEE management of trauma and cardiothoracic patients.
The hTEE Trauma Symposium will take place this Friday, January 18th from 1:30-3:15 PM at the JW Marriott Camelback Inn in Scottsdale, Arizona during the 26th Annual Scientific Assembly of the Eastern Association for the Surgery of Trauma (EAST). Faculty for the event include:
The hTEE Cardiac Support Symposium is scheduled for Monday, January 28th from 6:00-7:15 AM at the JW Marriott Los Angeles LA LIVE Hotel during the Society of Thoracic Surgeons (STS) 49th Annual Meeting. At this symposium concentrating on the hemodynamic management of high-acuity cardiac surgical patients, presenters include:
hTEE is the only technology in critical care that provides continuously available direct cardiac visualization. hTEE management improves patient outcomes, can shorten length of stay, and reduces intensive care cost. The established hTEE management program includes a proven Clinical Training Pathway for intensivists.
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare resources. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™, and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacorinc.com.